Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iterum Therapeutics (ITRM) Gains from Sales and Divestitures (2017 - 2022)

Historic Gains from Sales and Divestitures for Iterum Therapeutics (ITRM) over the last 6 years, with Q3 2022 value amounting to $48353.0.

  • Iterum Therapeutics' Gains from Sales and Divestitures fell 9231.88% to $48353.0 in Q3 2022 from the same period last year, while for Sep 2022 it was $48353.0, marking a year-over-year decrease of 9231.88%. This contributed to the annual value of $41961.0 for FY2021, which is 235385.96% up from last year.
  • Iterum Therapeutics' Gains from Sales and Divestitures amounted to $48353.0 in Q3 2022, which was down 9231.88% from $725328.0 recorded in Q2 2022.
  • Over the past 5 years, Iterum Therapeutics' Gains from Sales and Divestitures peaked at $725328.0 during Q2 2022, and registered a low of $1710.0 during Q4 2020.
  • Its 5-year average for Gains from Sales and Divestitures is $202526.4, with a median of $51906.0 in 2019.
  • Per our database at Business Quant, Iterum Therapeutics' Gains from Sales and Divestitures tumbled by 9536.89% in 2020 and then surged by 409516.04% in 2021.
  • Quarter analysis of 5 years shows Iterum Therapeutics' Gains from Sales and Divestitures stood at $103274.0 in 2018, then tumbled by 64.25% to $36924.0 in 2019, then plummeted by 95.37% to $1710.0 in 2020, then skyrocketed by 2353.86% to $41961.0 in 2021, then increased by 15.23% to $48353.0 in 2022.
  • Its last three reported values are $48353.0 in Q3 2022, $725328.0 for Q2 2022, and $578136.0 during Q1 2022.